Insulet Corp (PODD) company profile

Insulet Corporation develops, manufactures, and sells proprietary continuous insulin delivery devices designed for individuals with insulin-dependent diabetes. Its core offering is the Omnipod tubeless platform, which includes the Omnipod 5 Automated Insulin Delivery System, the Omnipod DASH Insulin Management System, and the legacy Classic Omnipod. In addition to insulin management systems, the company produces drug delivery pods utilized in Amgen's Neulasta Onpro kits to assist chemotherapy patients. Insulet serves individuals with type 1 and type 2 diabetes through commercial distribution partners, independent wholesalers supplying pharmacy networks, healthcare organizations, and direct consumer channels.

The company distributes its Omnipod product line across 25 countries, with Omnipod 5 commercially available in 19 of those markets. Product manufacturing takes place at automated company-owned facilities located in Acton, Massachusetts, and Johor, Malaysia, alongside contract manufacturing lines in China and an additional facility under development in Costa Rica. Insulet operates facilities and management from Acton, Massachusetts.

Summary of the business section of Insulet's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

“Per Share Total Initial public offering price $ 15.00 $ 115,500,000 Underwriting discount $ 1.05 $ 8,085,000 Proceeds to Insulet Corporation, before expenses $ 13.95 $ 107,415,000 We have granted the underwriters an option for a period of 30 days to purchase up to 1,155,000 additional shares of our common stock on”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

“As of December 31, 2025, we had approximately 5,400 full-time employees, representing a 38% increase over the prior year.”